A Phase 2 interventional study of LY2484595 and Atorvastatin in Dyslipidemia, sponsored by Eli Lilly and Company. Completed at 59 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-22.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 20th largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2010, is one of 10 in phase 2, and was the 42nd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 398 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 75 interventional studies. Of the 69 that completed or were terminated, 33 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 77 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
10 studies in Hypercholesterolemia by Eli Lilly and Company: 3 open now, 3 under way, none of them phase 3. Of 7 finished, 5 (71%) have results posted.
Among the 10 studies in Hypercholesterolemia by Eli Lilly and Company, this one is the only one that started in 2010, is one of 4 in phase 2, and was the 2nd registered.
Eli Lilly and Company’s Hypercholesterolemia studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, from their registry updates:
Among Eli Lilly and Company’s 10 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
The primary purpose of your participation in this study is to help answer the following research question(s)
Patients will be stratified according to baseline levels of serum triglycerides (\<150 or greater than or equal to 150 milligram/deciliter (mg/dL), HDL-C (\<45 or greater than or equal to 45 mg/dL for men; \<50 or greater than or equal to 50 mg/dL for women), and region (United States or Europe). After a diet lead-in and prior therapy washout phase, subjects meeting all entry criteria will be randomized to one of 10 double-blind treatment groups for a 12 week treatment phase. After randomization, patients will self-administer the study drugs once a day with a low fat meal as their first meal of the day.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
This study's enrollment of 398 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LY2484595 · Drug: Placebo for Statins
Drug: LY2484595 · Drug: Placebo for Statins
Drug: LY2484595 · Drug: Placebo for Statins
Drug: Placebo for LY2484595 · Drug: Placebo for Statins
Drug: Atorvastatin · Drug: Placebo for LY2484595
Drug: LY2484595 · Drug: Atorvastatin
Drug: Simvastatin · Drug: Placebo for LY2484595
Drug: LY2484595 · Drug: Simvastatin
Drug: Rosuvastatin · Drug: Placebo for LY2484595
Drug: LY2484595 · Drug: Rosuvastatin
Administered daily by mouth for 12 weeks
Administered daily by mouth for 12 weeks
Administered daily by mouth for 12 weeks
Administered daily by mouth for 12 weeks
Administered daily by mouth for 12 weeks
Administered daily by mouth for 12 weeks
Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 and Placebo
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 and Placebo
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Simvastatin or Rosuvastatin and Simvastatin/Rosuvastatin Monotherapy
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Simvastatin or Rosuvastatin and Simvastatin/Rosuvastatin Monotherapy
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Pharmacokinetics - LY2484595 Area Under the Concentration-Time Curve (AUC) at Steady-State
Time frame: Baseline up to 12 weeks
Percent Change From Baseline to 12 Weeks Endpoint in Plasma Cholesteryl Ester Transfer Protein (CETP) Activity
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Percent Change From Baseline to 12 Weeks Endpoint in Plasma Cholesteryl Ester Transfer Protein (CETP) Mass
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
The Number of Episodes of Rashes at Any Time From Baseline Through Week 12
All rash cases were adjudicated by a central dermatologist blinded to treatment assignment according to a study-specific Clinical Events Committee (CEC) charter. Rash events were assessed according to clinical relevance (high risk, low risk, not a relevant dermatosis, or insufficient documentation for determination). A participant could be reported in multiple categories.
Time frame: Baseline through Week 12
Change From Baseline to 12 Weeks Endpoint in Blood Pressure (BP)
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Change From Baseline to 12 Weeks Endpoint in Serum Aldosterone
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Change From Baseline to 12 Weeks Endpoint in Plasma Renin Activity
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Change From Baseline to 12 Weeks Endpoint in Serum Potassium
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Change From Baseline to 12 Weeks Endpoint in Serum Sodium
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Change From Baseline to 12 Weeks Endpoint in Serum Bicarbonate
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline, Week 12
Change From Baseline to 18 Weeks Endpoint in EuroQoL Questionnaire - 5 Dimensions (EQ-5D) Score
EQ-5D is a health-related, quality-of-life instrument. It allows participants to rate their health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, and mood. A single score 1 -3 is generated for each domain, with 1=no problem and 3= extreme problems. The outcome ratings on the 5 domains are mapped to a single index through an algorithm. The index ranges 0-1, with the higher score indicating a better health state perceived by the participants. LS Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Time frame: Baseline up to Week 18
| Milestone | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 40 | 39 | 42 | 38 | 41 | 35 | 42 | 40 | 40 | 41 |
| Took at least one dose of study drug | 40 | 38 | 40 | 38 | 41 | 35 | 41 | 40 | 39 | 41 |
| Completed | 35 | 34 | 32 | 36 | 35 | 30 | 34 | 33 | 34 | 32 |
| Not completed | 5 | 5 | 10 | 2 | 6 | 5 | 8 | 7 | 6 | 9 |
| Withdrew: Adverse event | 2 | 1 | 5 | 1 | 0 | 1 | 2 | 4 | 1 | 4 |
| Withdrew: Withdrawal by subject | 2 | 2 | 2 | 0 | 4 | 1 | 2 | 1 | 0 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 2 | 2 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| Withdrew: Abnormal lab/electrocardiogram result | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 1 | 2 | 0 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| percent change of mg/dL | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin |
|---|---|---|
| Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy | 1.4 ± 5.7 | 79.9 ± 6.0 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| percent change of mg/dL | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin |
|---|---|---|
| Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy | -33.6 ± 3.0 | -47.6 ± 3.2 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| percent change of mg/dL | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 and Placebo | 53.6 ± 5.6 | 94.6 ± 5.7 | 128.8 ± 5.8 | -3.0 ± 5.6 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| percent change of mg/dL | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 and Placebo | -13.6 ± 3.0 | -22.3 ± 3.0 | -35.9 ± 3.1 | 3.9 ± 3.0 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| percent change of mg/dL | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|
| Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Simvastatin or Rosuvastatin and Simvastatin/Rosuvastatin Monotherapy | 7.3 ± 5.5 | 86.6 ± 5.7 | 5.5 ± 5.7 | 94.0 ± 5.7 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| percent change of mg/dL | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|
| Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Simvastatin or Rosuvastatin and Simvastatin/Rosuvastatin Monotherapy | -34.9 ± 3.0 | -46.1 ± 3.1 | -38.8 ± 3.0 | -52.3 ± 3.0 |
| nanograms*hour/milliliter (ng*h/mL) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 100 mg LY2484595 + 40 mg Simvastatin | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|---|---|
| Pharmacokinetics - LY2484595 Area Under the Concentration-Time Curve (AUC) at Steady-State | 2300 ± 39.4 | 5900 ± 39.4 | 19700 ± 39.4 | 5500 ± 39.4 | 5620 ± 39.4 | 5960 ± 39.4 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| percent change of picomoles/mL/minute | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline to 12 Weeks Endpoint in Plasma Cholesteryl Ester Transfer Protein (CETP) Activity | -49.48 ± 3.75 | -70.80 ± 3.89 | -89.10 ± 4.00 | 12.12 ± 3.75 | -0.01 ± 3.81 | -72.00 ± 4.01 | -2.23 ± 3.80 | -64.64 ± 3.86 | -7.19 ± 3.80 | -73.24 ± 3.96 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| percent change of micrograms/mL (mcg/mL) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline to 12 Weeks Endpoint in Plasma Cholesteryl Ester Transfer Protein (CETP) Mass | 63.94 ± 5.54 | 92.27 ± 5.59 | 136.66 ± 5.83 | 0.58 ± 5.51 | -11.8 ± 5.48 | 62.98 ± 5.87 | -11.14 ± 5.50 | 65.92 ± 5.63 | -16.58 ± 5.62 | 64.08 ± 5.81 |
All rash cases were adjudicated by a central dermatologist blinded to treatment assignment according to a study-specific Clinical Events Committee (CEC) charter. Rash events were assessed according to clinical relevance (high risk, low risk, not a relevant dermatosis, or insufficient documentation for determination). A participant could be reported in multiple categories.
| events | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|---|---|---|---|---|---|
| High Risk (HR)- Angioedema | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| HR - Insufficient Documentation for Determination | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Low Risk | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Not a Relevant Dermatoses | 4 | 5 | 3 | 0 | 1 | 2 | 6 | 4 | 0 | 1 |
| Insufficient Documentation for Determination | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| millimeters of mercury (mmHg) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|---|---|---|---|---|---|
| Diastolic BP | 1.1 ± 1.1 | 0.8 ± 1.1 | 1.2 ± 1.2 | 1.6 ± 1.1 | 0.2 ± 1.1 | 1.2 ± 1.2 | -1.5 ± 1.1 | 2.3 ± 1.2 | 2.2 ± 1.1 | -0.1 ± 1.1 |
| Systolic BP | 4.4 ± 1.8 | 4.3 ± 1.8 | 1.4 ± 1.8 | 2.8 ± 1.7 | 0.2 ± 1.7 | 2.1 ± 1.9 | 0.0 ± 1.7 | 2.3 ± 1.8 | 0.0 ± 1.8 | 3.8 ± 1.8 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| nanogram/deciliter (ng/dL) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to 12 Weeks Endpoint in Serum Aldosterone | -0.5 ± 0.9 | 1.0 ± 0.9 | -0.3 ± 0.9 | -1.0 ± 0.9 | -1.0 ± 0.9 | 0.4 ± 0.9 | 0.0 ± 0.9 | -1.7 ± 0.9 | -2.5 ± 0.9 | 0.0 ± 0.9 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| nanograms/milliliter/hour (ng/mL/h) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to 12 Weeks Endpoint in Plasma Renin Activity | -0.06 ± 0.34 | -0.11 ± 0.34 | -0.58 ± 0.35 | -0.30 ± 0.34 | -0.58 ± 0.34 | -0.26 ± 0.37 | -0.16 ± 0.34 | 0.00 ± 0.34 | -0.86 ± 0.33 | -0.29 ± 0.35 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| milliequivalents/Liter | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to 12 Weeks Endpoint in Serum Potassium | -0.04 ± 0.05 | 0.01 ± 0.05 | -0.02 ± 0.05 | -0.08 ± 0.05 | 0.09 ± 0.05 | 0.08 ± 0.05 | 0.03 ± 0.05 | 0.02 ± 0.05 | -0.07 ± 0.05 | -0.05 ± 0.05 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| milliequivalents/Liter | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to 12 Weeks Endpoint in Serum Sodium | 0.3 ± 0.4 | 0.3 ± 0.4 | 0.5 ± 0.4 | 0.1 ± 0.4 | 1.3 ± 0.4 | 0.6 ± 0.4 | 0.8 ± 0.4 | 0.9 ± 0.4 | 0.5 ± 0.4 | 0.3 ± 0.4 |
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| milliequivalents/Liter | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to 12 Weeks Endpoint in Serum Bicarbonate | 0.40 ± 0.36 | 0.60 ± 0.36 | 0.51 ± 0.37 | 0.27 ± 0.36 | 0.10 ± 0.36 | 0.58 ± 0.38 | 1.04 ± 0.35 | 0.58 ± 0.37 | 0.78 ± 0.36 | 1.25 ± 0.37 |
EQ-5D is a health-related, quality-of-life instrument. It allows participants to rate their health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, and mood. A single score 1 -3 is generated for each domain, with 1=no problem and 3= extreme problems. The outcome ratings on the 5 domains are mapped to a single index through an algorithm. The index ranges 0-1, with the higher score indicating a better health state perceived by the participants. LS Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
| units on a scale | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin |
|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to 18 Weeks Endpoint in EuroQoL Questionnaire - 5 Dimensions (EQ-5D) Score | 0.008 ± 0.014 | 0.002 ± 0.014 | 0.012 ± 0.014 | -0.001 ± 0.014 | -0.002 ± 0.014 | -0.006 ± 0.014 | -0.001 ± 0.014 | -0.001 ± 0.013 | 0.014 ± 0.014 | -0.047 ± 0.013 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 30 mg LY2484595 Monotherapy | — | 0/40 (0%) | 22/40 (55%) |
| 100 mg LY2484595 Monotherapy | — | 0/38 (0%) | 25/38 (65.8%) |
| 500 mg LY2484595 Monotherapy | — | 1/40 (2.5%) | 21/40 (52.5%) |
| Placebo | — | 0/38 (0%) | 23/38 (60.5%) |
| 20 mg Atorvastatin Monotherapy | — | 0/41 (0%) | 29/41 (70.7%) |
| 100 mg LY2484595 + 20 mg Atorvastatin | — | 1/35 (2.9%) | 22/35 (62.9%) |
| 40 mg Simvastatin Monotherapy | — | 1/41 (2.4%) | 29/41 (70.7%) |
| 100 mg LY2484595 + 40 mg Simvastatin | — | 0/40 (0%) | 27/40 (67.5%) |
| 10 mg Rosuvastatin Monotherapy | — | 0/39 (0%) | 31/39 (79.5%) |
| 100 mg LY2484595 + 10 mg Rosuvastatin | — | 1/41 (2.4%) | 27/41 (65.9%) |
| 30 mg LY2484595 Monotherapy Follow-Up | — | 0/40 (0%) | 7/40 (17.5%) |
| 100 mg LY2484595 Monotherapy Follow-Up | — | 0/38 (0%) | 4/38 (10.5%) |
| 500 mg LY2484595 Monotherapy Follow-Up | — | 1/40 (2.5%) | 6/40 (15%) |
| Placebo Follow-Up | — | 1/38 (2.6%) | 8/38 (21.1%) |
| 20 mg Atorvastatin Monotherapy Follow-Up | — | 0/41 (0%) | 6/41 (14.6%) |
| 100 mg LY2484595 + 20 mg Atorvastatin Follow-Up | — | 0/35 (0%) | 8/35 (22.9%) |
| 40 mg Simvastatin Monotherapy Follow-Up | — | 0/41 (0%) | 7/41 (17.1%) |
| 100 mg LY2484595 + 40 mg Simvastatin Follow-Up | — | 0/40 (0%) | 4/40 (10%) |
| 10 mg Rosuvastatin Monotherapy Follow-Up | — | 0/39 (0%) | 6/39 (15.4%) |
| 100 mg LY2484595 + 10 mg Rosuvastatin Follow-Up | — | 0/41 (0%) | 5/41 (12.2%) |
| Event | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin | 30 mg LY2484595 Monotherapy Follow-Up | 100 mg LY2484595 Monotherapy Follow-Up | 500 mg LY2484595 Monotherapy Follow-Up | Placebo Follow-Up | 20 mg Atorvastatin Monotherapy Follow-Up | 100 mg LY2484595 + 20 mg Atorvastatin Follow-Up | 40 mg Simvastatin Monotherapy Follow-Up | 100 mg LY2484595 + 40 mg Simvastatin Follow-Up | 10 mg Rosuvastatin Monotherapy Follow-Up | 100 mg LY2484595 + 10 mg Rosuvastatin Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 1/35 | 0/41 | 0/40 | 0/39 | 0/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| InfluenzaInfections and infestations | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 | 0/40 | 0/38 | 0/40 | 1/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| BursitisMusculoskeletal and connective tissue disorders | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 | 0/40 | 0/38 | 1/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| Anal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/40 | 0/38 | 1/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| Metastases to lymph nodesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/40 | 0/38 | 1/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| FallInjury, poisoning and procedural complications | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 1/41 | 0/40 | 0/39 | 0/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| Hip fractureInjury, poisoning and procedural complications | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 1/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 1/41 | 0/40 | 0/39 | 0/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| Event | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin | 30 mg LY2484595 Monotherapy Follow-Up | 100 mg LY2484595 Monotherapy Follow-Up | 500 mg LY2484595 Monotherapy Follow-Up | Placebo Follow-Up | 20 mg Atorvastatin Monotherapy Follow-Up | 100 mg LY2484595 + 20 mg Atorvastatin Follow-Up | 40 mg Simvastatin Monotherapy Follow-Up | 100 mg LY2484595 + 40 mg Simvastatin Follow-Up | 10 mg Rosuvastatin Monotherapy Follow-Up | 100 mg LY2484595 + 10 mg Rosuvastatin Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/40 | 3/38 | 1/40 | 6/38 | 4/41 | 6/35 | 4/41 | 4/40 | 9/39 | 3/41 | 1/40 | 0/38 | 1/40 | 2/38 | 0/41 | 0/35 | 0/41 | 0/40 | 1/39 | 0/41 |
| NauseaGastrointestinal disorders | 0/40 | 0/38 | 3/40 | 1/38 | 1/41 | 3/35 | 1/41 | 2/40 | 1/39 | 4/41 | 1/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| HeadacheNervous system disorders | 2/40 | 0/38 | 0/40 | 1/38 | 4/41 | 0/35 | 0/41 | 2/40 | 2/39 | 3/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 1/41 | 0/40 | 0/39 | 0/41 |
| DiarrhoeaGastrointestinal disorders | 0/40 | 2/38 | 3/40 | 1/38 | 1/41 | 2/35 | 1/41 | 2/40 | 2/39 | 2/41 | 1/40 | 0/38 | 0/40 | 0/38 | 1/41 | 0/35 | 0/41 | 0/40 | 1/39 | 0/41 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/40 | 1/38 | 2/40 | 0/38 | 3/41 | 2/35 | 0/41 | 3/40 | 1/39 | 2/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| RashSkin and subcutaneous tissue disorders | 1/40 | 2/38 | 1/40 | 0/38 | 0/41 | 0/35 | 2/41 | 3/40 | 0/39 | 1/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| FlatulenceGastrointestinal disorders | 0/40 | 0/38 | 0/40 | 2/38 | 0/41 | 0/35 | 1/41 | 1/40 | 0/39 | 3/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| Upper respiratory tract infectionInfections and infestations | 0/40 | 0/38 | 0/40 | 0/38 | 1/41 | 1/35 | 3/41 | 2/40 | 0/39 | 1/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 1/35 | 0/41 | 0/40 | 1/39 | 1/41 |
| Blood pressure systolic increasedInvestigations | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 1/35 | 0/41 | 0/40 | 0/39 | 3/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| DizzinessNervous system disorders | 0/40 | 2/38 | 0/40 | 0/38 | 0/41 | 1/35 | 0/41 | 2/40 | 0/39 | 3/41 | 0/40 | 0/38 | 0/40 | 0/38 | 0/41 | 0/35 | 0/41 | 0/40 | 0/39 | 0/41 |
| Age, Continuous(years) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 58.5 ± 11.1 | 58.5 ± 9.2 | 58.8 ± 12.2 | 55.2 ± 10.5 | 57.8 ± 11.3 | 57.4 ± 11.8 | 61.3 ± 10.0 | 58.4 ± 9.0 | 57.4 ± 12.6 | 59.7 ± 10.1 | 58.3 ± 10.8 |
| Sex: Female, Male(Participants) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 23 | 22 | 21 | 20 | 26 | 18 | 29 | 25 | 13 | 23 | 220 |
| Male | 17 | 16 | 19 | 18 | 15 | 17 | 12 | 15 | 26 | 18 | 173 |
| Ethnicity (NIH/OMB)(Participants) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 2 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 19 |
| Not Hispanic or Latino | 27 | 28 | 29 | 26 | 29 | 25 | 29 | 30 | 25 | 34 | 282 |
| Unknown or Not Reported | 11 | 7 | 9 | 9 | 10 | 8 | 10 | 9 | 13 | 6 | 92 |
| Race (NIH/OMB)(Participants) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 1 | 4 | 1 | 1 | 2 | 2 | 0 | 3 | 1 | 20 |
| White | 33 | 36 | 35 | 36 | 39 | 33 | 39 | 39 | 35 | 40 | 365 |
| More than one race | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 22 | 23 | 22 | 22 | 23 | 18 | 21 | 23 | 22 | 22 | 218 |
| Poland | 2 | 2 | 2 | 0 | 2 | 1 | 1 | 2 | 0 | 4 | 16 |
| Denmark | 12 | 9 | 8 | 10 | 10 | 9 | 12 | 11 | 11 | 10 | 102 |
| Germany | 2 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 2 | 0 | 11 |
| Netherlands | 2 | 2 | 5 | 5 | 4 | 5 | 6 | 2 | 4 | 4 | 39 |
| United Kingdom | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 7 |
| Weight(kilogram) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 84.6 ± 23.2 | 79.9 ± 18.3 | 82.6 ± 20.6 | 89.3 ± 18.5 | 81.4 ± 16.4 | 87.4 ± 22.4 | 79.6 ± 15.4 | 84.5 ± 16.7 | 85.7 ± 19.4 | 82.2 ± 18.0 | 83.6 ± 19.0 |
| Body Mass Index (BMI)(kilogram/square meter (kg/m²)) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 29.8 ± 7.8 | 27.6 ± 5.7 | 29.0 ± 5.6 | 29.8 ± 6.1 | 28.8 ± 5.1 | 30.0 ± 7.5 | 28.3 ± 5.0 | 29.9 ± 5.3 | 28.3 ± 4.2 | 28.4 ± 5.3 | 29.0 ± 5.8 |
| High-Density Lipoprotein Cholesterol (HDL-C)(milligram/deciliter (mg/dL)) | 30 mg LY2484595 Monotherapy | 100 mg LY2484595 Monotherapy | 500 mg LY2484595 Monotherapy | Placebo | 20 mg Atorvastatin Monotherapy | 100 mg LY2484595 + 20 mg Atorvastatin | 40 mg Simvastatin Monotherapy | 100 mg LY2484595 + 40 mg Simvastatin | 10 mg Rosuvastatin Monotherapy | 100 mg LY2484595 + 10 mg Rosuvastatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 54.7 ± 12.0 | 57.0 ± 14.1 | 54.7 ± 16.3 | 53.0 ± 11.8 | 53.9 ± 17.0 | 55.7 ± 18.2 | 57.3 ± 16.2 | 53.7 ± 13.6 | 53.5 ± 15.2 | 57.8 ± 18.1 | 55.1 ± 15.3 |
2 further baseline measures are reported on the registry.
The record gives a start of Apr 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2018, 6 years 9 months after primary completion. A results delay was requested in Sep 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Evacetrapib · Atorvastatin · Simvastatin · Rosuvastatin